MRA-669_杂交瘤W3.5抗伯氏疟原虫红细胞期外抗原(细胞库)
产品图片
货号/SKU
MRA-669
货号/规格
EA
库存与交货期
3-8周
人民币价格
14000
试剂海关审批
A/B级风险物质只能直接使用人购买并持有实验室有效资质,其它询客服确认
国外采购
支持/部分限制一年内购买数量
厂牌
BEI Resources(ATCC)
产品基础信息
生物安全等级建议分类:美国、1
产品描述信息
MRA-669?? Hybridoma W3.5 Anti-Plasmodium berghei Erythrocytic-Stage Exoantigen(Cell Banks)|Plasmodium berghei|Hybridoma W3.5 Anti-Plasmodium berghei Erythrocytic-Stage Exoantigen|-100°C or colder, preferably in the vapor phase of a liquid nitrogen freezer|MF WiserAcknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Hybridoma W3.5 Anti-Plasmodium berghei Erythrocytic-Stage Exoantigen, MRA-669, contributed by Mark F. Wiser."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.
This item is currently in our production queue. Please allow ample time for distribution lots to be made available.
The murine hybridoma cell line, W3.5, was generated by the fusion of mouse myeloma cells (X63.Ag8.6.5.3) with splenocytes from immunized mice, which were infected with Plasmodium berghei (P. berghei) and cured with chloroquine twice. This reagent was authenticated by the contributor and tested for mycoplasma.
Each vial of MRA-669 contains approximately 0.5 mL of hybridoma cells (5 × 106 cells/mL) in cell culture medium supplemented with 10% dimethylsulfoxide (DMSO).
Hybridoma W3.5 produces IgG2b antibody that specifically recognizes an unknown 31 kDa protein of Plasmodium berghei and an unidentified 13 kDa to 18 kDa protein associated with inclusions in the cytoplasm of erythrocytes infected with rodent Plasmodium species. Applications include Western Blot, immunoprecipitation and immunofluorescence (produced external to the parasite and within the host erythrocyte cytoplasm).
Wiser, M. F. "Characterization of Monoclonal Antibodies Directed against Erythrocytic Stage Antigens of Plasmodium berghei." Eur. J. Cell Biol. 42 (1986): 45-51. PubMed: 3539609.
Wiser, M. F. "Plasmodium Antigens External to the Parasite But with the Infected Erythrocyte." Parasitol. Res. 75 (1989): 206-211. PubMed: 2652137.
This item is currently in our production queue. Please allow ample time for distribution lots to be made available.
The murine hybridoma cell line, W3.5, was generated by the fusion of mouse myeloma cells (X63.Ag8.6.5.3) with splenocytes from immunized mice, which were infected with Plasmodium berghei (P. berghei) and cured with chloroquine twice. This reagent was authenticated by the contributor and tested for mycoplasma.
Each vial of MRA-669 contains approximately 0.5 mL of hybridoma cells (5 × 106 cells/mL) in cell culture medium supplemented with 10% dimethylsulfoxide (DMSO).
Hybridoma W3.5 produces IgG2b antibody that specifically recognizes an unknown 31 kDa protein of Plasmodium berghei and an unidentified 13 kDa to 18 kDa protein associated with inclusions in the cytoplasm of erythrocytes infected with rodent Plasmodium species. Applications include Western Blot, immunoprecipitation and immunofluorescence (produced external to the parasite and within the host erythrocyte cytoplasm).
Wiser, M. F. "Characterization of Monoclonal Antibodies Directed against Erythrocytic Stage Antigens of Plasmodium berghei." Eur. J. Cell Biol. 42 (1986): 45-51. PubMed: 3539609.
Wiser, M. F. "Plasmodium Antigens External to the Parasite But with the Infected Erythrocyte." Parasitol. Res. 75 (1989): 206-211. PubMed: 2652137.
主要内容
此项目的每个订单数量限制为1.此商品每年可订购两次.通过此限制的订单将在发货前发送至NIAID进行批准.
此项目目前处于我们的生产队列中.请允许充足的时间进行分销批次.
鼠杂交瘤细胞系W3.5由小鼠骨髓瘤细胞(X63.Ag8.5.3)与免疫小鼠的脾细胞融合产生,该小鼠感染疟原虫(P. Berghei)并用氯喹治疗两次.该试剂被贡献者认证并对支原体进行测试.
MRA-669的每个小瓶中含有大约0.5ml的细胞培养基中的杂交瘤细胞(5×10 6℃),其补充有10%二甲基磺砜(DMSO).
杂交瘤W3.5产生IgG2B抗体,其特异性识别出一种未知的31kDa蛋白的苯乙烯(Berghei)和未识别的13kDa至18kDa蛋白质,其与感染啮齿动物的红细胞的细胞质中的夹杂物相关疟原虫物种.应用包括蛋白质印迹,免疫沉淀和免疫荧光(寄生虫外部和宿主红细胞细胞质内产生).
Wiser,M. f.“针对疟原虫的红细胞阶段抗原的单克隆抗体的表征,Berghei ”. EUR. J.细胞生物. 42(1986):45-51. PubMed:3539609.
Wiser,M. F.“疟原虫寄生虫外部的抗原,但受感染的红细胞.” 寄生醇. res. 75(1989):206-211. PubMed:2652137.
厂牌介绍
BEI Resources 由美国国家过敏和传染病研究所 ( NIAID )成立,旨在为研究 A、B 和 C 类优先病原体、新兴传染病病原体、非病原微生物和其他相关微生物材料提供试剂、工具和信息到研究界。BEI Resources 获取、验证和生产科学家进行基础研究和开发改进的诊断测试、疫苗和疗法所需的试剂。通过将这些功能集中在 BEI Resources 中,可以监控科学界对这些材料的访问和使用,并确保试剂的质量控制。
除了为传染病界提供材料外,BEI Resources 还鼓励和支持研究人员和机构的材料存放。使用 BEI Resources存放材料对研究人员和研究社区有许多优势,包括安全存储、社区访问和分发;同时保护存款人的知识产权。只要有需要,BEI 资源库将作为研究人员的资源进行维护。您在 BEI Resources 的存款是一项有助于未来研究的长期投资。
BEI Resources 自 2003 年起由美国典型培养物保藏中心 (ATCC) 根据合同管理。2016 年 5 月, ATCC获得了一份为期七年的继续管理 BEI Resources的合同。合同范围已扩大到更全面的研究目录材料,包括由其他政府支持的研究项目存放的材料,将提供给生物防御和新兴传染病科学界。真菌、寄生虫、载体和其他相关材料已添加到现有的细菌、病毒和毒素试剂中,涵盖 NIAID A、B 和 C 类优先病原体和 NIAID 指定的新发传染病病原体和生物。
品牌标识
可能感兴趣的内容
2023-07-18
2019-06-24
2024-08-16
2022-04-01
2024-08-16
2021-12-21
2024-03-25
2021-12-21
2022-03-22
2022-04-01
2021-12-21
2021-12-21
2022-04-01
2024-01-21
2021-12-21
2021-12-21